Local cerebral blood flow in the dog during intravenous infusion of dopamine.
Local cerebral blood flow was measured in anaesthetized beagle dogs by the hydrogen clearance method. Dopamine was administered as a continuous intravenous infusion of varying doses. The changes in local cerebral blood flow induced by dopamine were similar at the different locations; i.e., the caudate nucleus, thalamus, frontal and parietal cortex. Blood flow responded to dopamine in the following ways: low dose (less than 2 micrograms/kg/min): blood flow decreased or remained unchanged; moderate doses (2--6 micrograms/kg/min): blood flow increased at all electrodes; high doses (7--20 micrograms/kg/min): blood flow decreased once again. The decrease in blood flow could be inhibited by the alpha-adrenergic receptor antagonist phentolamine or by the serotonin receptor antagonist methysergide. This indicates that the constrictor effect of dopamine on cerebral blood vessels is mediated via alpha-adrenergic receptors as well as via serotonin receptors. The increase in cerebral flow could be inhibited by the dopamine receptor antagonist haloperidol, indicating vascular dopamine receptors in the brain with a dilating effect. When the vasoconstrictor activity of dopamine is blocked, the single response to a dopamine infusion is a blood flow increase. This might be beneficial in the clinical situation of symptomatic vasospasm.
D000241:Adenosine / Q000494:pharmacology; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D002536:Cerebral Arteries / Q000187:drug effects; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004285:Dogs; D004298:Dopamine / Q000008:administration & dosage / Q000494:pharmacology*; D018492:Dopamine Antagonists; D006220:Haloperidol / Q000494:pharmacology; D000860:Hypoxia / Q000503:physiopathology; D007263:Infusions, Parenteral; D008784:Methysergide / Q000494:pharmacology; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism; D011985:Receptors, Serotonin / Q000187:drug effects; D012701:Serotonin; D012702:Serotonin Antagonists; D014661:Vasoconstriction / Q000187:drug effects
D018492:Dopamine Antagonists; D011954:Receptors, Dopamine; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D012701:Serotonin; D006220:Haloperidol; D000241:Adenosine; D001058:Apomorphine; D004298:Dopamine; D008784:Methysergide